NCT07277855: FLS

Floor-Lift Series Pulmonary Rehabilitation for COPD: Short- and Long-Term Outcomes in a North African Setting

Active, enrolled NA Last updated 11 December 2025

What this trial tests

NA trial testing Floor-Lift Series (FLS) Pulmonary Rehabilitation Program in COPD (Chronic Obstructive Pulmonary Disease) in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2024

Primary endpoint
1 December 2026

30 June 2027

Quick facts

Lead sponsor	Benazzouz Redouene Sid Ahmed
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	1 December 2024
Primary completion	1 December 2026
Estimated completion	30 June 2027
Sites	1 location across Algeria

Drugs / interventions tested

• Floor-Lift Series (FLS) Pulmonary Rehabilitation Program

Conditions studied

• COPD (Chronic Obstructive Pulmonary Disease) — all drugs for COPD (Chronic Obstructive Pulmonary Disease) →
• Muscle Weakness | Patient — all drugs for Muscle Weakness | Patient →

Sponsor

Benazzouz Redouene Sid Ahmed

Who can join

18 and older, any sex, with COPD (Chronic Obstructive Pulmonary Disease) or Muscle Weakness | Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and functional disability, with pulmonary rehabilitation (PR) representing one of the most effective non-pharmacological interventions. However, access to conventional PR programs remains extremely limited in many regions, particularly in North Africa, where resources, infrastructure, and patient adherence pose major challenges.

The Floor-Lift Series (FLS) program was developed as a culturally adapted, equipment-free, and low-cost PR alternative. It is based on progressive floor-to-stand transitions - movements deeply integrated into daily routines and familiar in the local cultural context - to enhance feasibility and adherence.

This prospective quasi-experimental study will evaluate both the short-term and long-term effects of the FLS program in COPD patients with baseline muscle dysfunction limiting their ability to rise from the floor. The short-term phase involves a 9-week intervention combining supervised and home-based training in three progressive stages (initial, intermediate, and consolidation). The long-term phase includes follow-up assessments at 18 months to evaluate sustained adherence and maintenance of clinical and functional improvements.

The primary outcome is the completion rate, defined as achieving ≥22 daily floor-lift repetitions during the final intervention phase and maintaining adherence at long-term follow-ups. Secondary outcomes include changes in dyspnea (mMRC), exertional effort (Borg CR10), disease impact (CAT), mobility (Timed Up and Go), flexibility (fingertip-to-floor distance), exercise capacity (6-minute walk test and 1-minute sit-to-stand test), and the composite BODE index.

Safety and psychosocial factors influencing adherence will be monitored throughout the study. The trial aims to provide evidence for a scalable, culturally relevant rehabilitation model for COPD management in resource-limited settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.